Page 80 - 《中国药房》2023年21期

[ 8 ] 张妮，龚莉，王琳，等. 基于FDA不良事件数据库和指定 （3）：E209-E216.
医疗事件对氯喹和羟氯喹不良反应信号的检测与评价 [18] ISMAIL A L S，YASSIN M A. Nilotinib-induced diabetes
[J]. 中国医院药学杂志，2020，40（18）：1921-1928. mellitus in a young female with chronic myeloid leukemia
ZHANG N，GONG L，WANG L，et al. Detection and [J]. Cureus，2020，12（9）：e10277.
evaluation of adverse drug reaction signals of chloroquine [19] RODRIGUES-SANTOS P，LÓPEZ-SEJAS N，ALMEIDA
and hydroxychloroquine based on FDA adverse event da‐ J S，et al. Effect of age on NK cell compartment in chronic
tabase and designated medical event[J]. Chin J Hosp myeloid leukemia patients treated with tyrosine kinase
Pharm，2020，40（18）：1921-1928. inhibitors[J]. Front Immunol，2018，9：2587.
[ 9 ] JIANG T T，SU H，LI Y P，et al. Post-marketing safety of [20] PITA-LÓPEZ M L，PERA A，SOLANA R. Adaptive
+
immunomodulatory drugs in multiple myeloma：a pharma‐ memory of human NK-like CD8 T-cells to aging，and vi‐
covigilance investigation based on the FDA adverse event ral and tumor antigens[J]. Front Immunol，2016，7：616.
reporting system[J]. Front Pharmacol，2022，13：989032. [21] VALENT P，HADZIJUSUFOVIC E，HOERMANN G，
[10] European Medical Agency. Human regulatory [EB/OL]. et al. Risk factors and mechanisms contributing to TKI-
[2023-03-21]. https：//www. ema. europa. eu/en/human- induced vascular events in patients with CML[J]. Leuk
regulatory/post-authorisation. Res，2017，59：47-54.
[11] 阮一，张妮，郑晓媛.基于FAERS的替格瑞洛及氯吡格雷相 [22] 王珂，尹列芬，杨欢，等. 酪氨酸激酶抑制剂治疗慢性粒
关出血事件信号挖掘[J].中国药业，2023，32（4）：102-106. 细胞白血病的不良反应及处理的研究进展[J]. 实用药物
与临床，2022，25（1）：87-91.
RUAN Y，ZHANG N，ZHENG X Y. Signal mining of
WANG K，YIN L F，YANG H，et al. Adverse events of
hemorrhage events related to ticagrelor and clopidogrel
tyrosine kinase inhibitors in the treatment of chronic
based on FAERS database[J]. China Pharm，2023，32（4）：
myeloid leukemia and the management[J]. Pract Pharm
102-106.
Clin Remedies，2022，25（1）：87-91.
[12] FACHI M M，TONIN F S，LEONART L P，et al. Haema‐
[23] WANG S F，DESIKAN S P，JEFFREY J，et al. Delayed
tological adverse events associated with tyrosine kinase in‐
acute pancreatitis induced by nilotinib in a patient with
hibitors in chronic myeloid leukaemia：a network meta-
chronic myeloid leukemia attaining sustained complete
analysis[J]. Br J Clin Pharmacol，2019，85（10）：2280-
molecular response[J]. eJHaem，2020，1（1）：309-311.
2291.
[24] KANTARJIAN H M，HUGHES T P，LARSON R A，et al.
[13] WANG Z，JIANG L Y，YAN H，et al. Adverse events asso‐
Long-term outcomes with frontline nilotinib versus ima‐
ciated with nilotinib in chronic myeloid leukemia：mecha‐
tinib in newly diagnosed chronic myeloid leukemia in
nisms and management strategies[J]. Expert Rev Clin
chronic phase：ENESTnd 10-year analysis[J]. Leukemia，
Pharmacol，2021，14（4）：445-456.
2021，35（2）：440-453.
[14] KAKADIA B，THAKKAR R，SANBORN E，et al.
[25] KASSAR O，MALLEK R，BEN SAID F，et al. Aplastic
Nilotinib-associated atherosclerosis presenting as multifo‐
anemia secondary to tyrosine kinase inhibitor therapy in a
cal intracranial stenosis and acute stroke[J]. J Stroke Cere‐
patient with chronic myeloid leukemia[J]. J Oncol Pharm
brovasc Dis，2021，30（8）：105883.
Pract，2022，28（2）：504-507.
[15] CAMPIA U，GERHARD-HERMAN M，PIAZZA G，et al.
[26] SONG I C，YEON S H，LEE M W，et al. Pulmonary hy‐
Peripheral artery disease：past，present，and future[J]. Am
pertension in patients with chronic myeloid leukemia[J].
J Med，2019，132（10）：1133-1141.
Medicine，2021，100（33）：e26975.
[16] 王少霞，陈娇娇，高婷，等. 基于FAERS数据库的酪氨酸 [27] SOLINC J，RAIMBAULT-MACHADO J，DIERICK F，
激酶抑制剂致药品不良反应信号的挖掘与分析[J]. 中国
et al. Platelet-derived growth factor receptor type α activa‐
医院用药评价与分析，2023，23（4）：498-501，505. tion drives pulmonary vascular remodeling via progenitor
WANG S X，CHEN J J，GAO T，et al. Mining and analy‐ cell proliferation and induces pulmonary hypertension[J].
sis of adverse drug reaction signals induced by tyrosine J Am Heart Assoc，2022，11（7）：e023021.
kinase inhibitors based on FAERS database[J]. Eval Anal [28] UGWU N I，OKOYE A E，UGWU C N，et al. Chronic
Drug Use Hosp China，2023，23（4）：498-501，505. myeloid leukaemia with sudden bilateral deafness and leg
[17] JANSSEN L，HOPMAN M T E，SWAANS G J A，et al. ulcer associated with hydroxyurea therapy[J]. West Afr J
Impact of tyrosine kinase inhibitors on glucose control Med，2021，38（5）：502-506.
and insulin regulation in patients with chronic myeloid （收稿日期：2023-05-16 修回日期：2023-10-10）
leukemia[J]. Am J Physiol Endocrinol Metab，2023，324 （编辑：胡晓霖）

· 2630 · China Pharmacy 2023 Vol. 34 No. 21 中国药房 2023年第34卷第21期